High levels of endogenous circulating oestrogens ([Hankinson and Eliassen, 2007](#bib18){ref-type="other"}) and use of exogenous oestrogens ([Beral, 2003](#bib5){ref-type="other"}) have both been associated with increased breast cancer risk. Isoflavones and lignans are plant compounds structurally similar to 17*β*-oestrodiol known as phyto-oestrogens, capable of oestrogen receptor binding ([Kuiper *et al*, 1998](#bib33){ref-type="other"}; [Mueller *et al*, 2004](#bib42){ref-type="other"}). Isoflavones are mostly found in soybean products, which are a staple of the Asian diet, whereas lignans are the principal group of phyto-oestrogens in Western diets. Lignans are more widespread in foods than isoflavones and are present in grain cereals, vegetables, seeds, tea and coffee ([Mazur, 1998a](#bib36){ref-type="other"}; [Mazur *et al*, 1998b](#bib37){ref-type="other"}). Microflora in the colon ([Setchell *et al*, 1981](#bib50){ref-type="other"}) convert plant lignans into enterolignans, which are detectable in blood and urine. Their levels have been correlated with the amount of plant lignans ingested ([Nesbitt *et al*, 1999](#bib43){ref-type="other"}).

In a recent meta-analysis, an inverse dose-response relationship was shown between breast cancer risk and soy-food intake in Asian, but not in Western women ([Wu *et al*, 2008](#bib62){ref-type="other"}). Lignans have been shown to exhibit anti-carcinogenic properties ([Wang *et al*, 1994](#bib60){ref-type="other"}; [Prasad 2000](#bib48){ref-type="other"}; [Bergman Jungeström *et al*, 2007](#bib6){ref-type="other"}), and it is hypothesised that exposure to high levels may be associated with a reduction in breast cancer risk. However, results from a number of studies in Western populations have been variable. The aim of our systematic review was to establish whether an association exists between lignan exposure and breast cancer risk, and to quantify the association through meta-analyses to inform evidence-based dietary guidelines.

Materials and methods
=====================

A systematic search of Ovid Medline (US National Library of Medicine, Bethesda, MD, USA), BIOSIS (Thompson Reuters, NY, USA) and EMBASE (Reed Elsevier PLC, Amsterdam, The Netherlands) databases for relevant studies published up to and including the date, 30 September 2008 was carried out. Relevant studies included at least one keyword or Medical Subject Heading from each of the following; (i) plant lignans (matairesinol, secoisolarisiresinol, pinoresinol and lariciresinol), (ii) enterolignans (enterolactone and enterodiol) and (iii) breast cancer. The search strategy excluded reviews, animal and cell culture studies but did not impose any language restrictions.

Abstracts and full texts, where required, were independently screened by two investigators to establish the suitability for inclusion. Studies had to be of case--control or cohort design, evaluating the risk of invasive breast cancer in relation to lignan exposure and reporting odds ratios (ORs) or relative risks, as well as 95% confidence intervals (95% CIs). Cited references were also reviewed for any studies that may have been missed in the database searches.

Eligible publications were then assessed independently by three reviewers. A structured form was used to extract information about the study, subjects\' characteristics including menopausal status, confounding factors and results. Wherever multiple publications of the same study were available, the paper with the most complete set of data was chosen.

Studies were then categorised as those: (i) assessing total plant lignan intake or intake of individual plant lignans if the total was not measured; (ii) investigating exposure to enterolignans (enterolactone and enterodiol) by using values produced from food by *in vitro* fermentation models; and (iii) examining enterolactone levels in the blood (either plasma or serum). The blood levels of enterodiol were measured in a small number of studies ([Piller *et al*, 2006b](#bib47){ref-type="other"}; [Verheus *et al*, 2007](#bib59){ref-type="other"}; [Ward *et al*, 2008](#bib61){ref-type="other"}) and were, therefore, not considered for analysis.

Separate meta-analyses were performed for each group of studies described in the Methods section using adjusted ORs or relative risks for the highest *vs* the lowest categories of exposure. If different levels of adjustment had been carried out, the results from the most fully adjusted model were used.

Random effects models were used to calculate pooled estimates, as we anticipated heterogeneity between observational studies ([DerSimonian and Laird, 1986](#bib13){ref-type="other"}). Study-specific weights in the random effects model were calculated and scaled to percentages. The *I*^2^-statistic was used to test for heterogeneity ([Higgins *et al*, 2003](#bib21){ref-type="other"}). Publication or selection bias was investigated by checking for asymmetry in funnel plots ([Egger *et al*, 1997](#bib15){ref-type="other"}).

Analysis was repeated and sub-divided by menopausal status (pre- and post-menopausal). Statistical analyses were performed using the STATA version 9.2 software (Stata Corporation 2005, College Station, TX, USA).

Results
=======

Following screening of abstracts and full texts and grouping into categories, 27 of the 33 articles identified were selected for data extraction. Multiple publications were identified for a number of studies. Four articles ([Grace *et al*, 2004](#bib17){ref-type="other"}; [McCann *et al*, 2006](#bib38){ref-type="other"}; [Thanos *et al*, 2006](#bib52){ref-type="other"}; [Piller *et al*, 2006b](#bib47){ref-type="other"}) were excluded, as they were based on smaller subgroup analysis of their respective larger studies. The format of certain results prevented their use, but were provided by the authors in a suitable form and therefore included in this study. Overall, 23 publications were used, providing data for 6 cohort, 6 nested case--control and 10 case--control studies. Each article contributed data to one or more meta-analyses resulting in 12 articles on plant lignan intake (see [Table 1](#tbl1){ref-type="table"}), 5 on enterolignan exposure (see [Table 2](#tbl2){ref-type="table"}) and 9 on blood enterolactone levels (see [Table 3](#tbl3){ref-type="table"}). Details of the adjustments made in each study (the most fully adjusted model was used in the meta-analysis) are shown in [Tables 1](#tbl1){ref-type="table"}, [2](#tbl2){ref-type="table"}, [3](#tbl3){ref-type="table"}.

There was no association between plant lignan intake and risk when 11 studies were combined, although there was a slight protective effect. The risk in the highest intake group was 0.93 times (95% CI: 0.83--1.03, *P*=0.15) that of the lowest intake group (see [Figure 1](#fig1){ref-type="fig"}). When studies were analysed by menopausal status, a statistically significant reduction in risk was seen with the highest intake category of plant lignans *vs* the lowest intake in post-menopausal women (7 studies, combined OR: 0.85, 95% CI: 0.78, 0.93, *P*\<0.001), with little sign of between-study heterogeneity (*I*^2^=0%, 95% CI: 0, 71, *P*=0.46) (see [Figure 2](#fig2){ref-type="fig"}). The same effect was not observed in pre-menopausal women (7 studies, combined OR: 0.97, 95% CI: 0.82, 1.15, *P*=0.73). The funnel plot of studies examining plant lignan intake and overall breast cancer risk showed symmetry, suggesting a lack of publication bias.

There was a statistically significant inverse association between enterolignan exposure and overall risk (combined OR: 0.73, 95% CI: 0.57, 0.92, *P*=0.009) ([Figure 3](#fig3){ref-type="fig"}), although there was marked heterogeneity (*I*^2^=63%, 95% CI: 0.0, 88, *P*=0.04), but there was no association between exposure and risk by menopausal status (pre-menopausal breast cancer risk: 3 studies, combined OR: 0.67, 95% CI: 0.44--1.02, *P*=0.06; post-menopausal: 2 studies, combined OR: 0.85, 95% CI: 0.72--1.01, *P*=0.06).

There was no association between blood enterolactone and breast cancer risk (combined OR: 0.82, 95% CI: 0.59--1.14, *P*=0.24) ([Figure 4](#fig4){ref-type="fig"}). Results of analysis by menopausal status were similar for both pre-menopausal women (5 studies, combined OR: 0.85, 95% CI: 0.45--1.59, *P*=0.61) and post-menopausal women (6 studies, combined OR: 0.86, 95% CI: 0.66, 1.14, *P*=0.28).

Discussion
==========

This is the first systematic review and meta-analysis of exposure to lignans and breast cancer risk based on studies using dietary assessments and serum measurements. Although exposure can be assessed by urine analysis, few studies have used this methodology and therefore, these were not included ([Ingram *et al*, 1997](#bib27){ref-type="other"}; [den Tonkelaar *et al*, 2001](#bib12){ref-type="other"}; [Dai *et al*, 2002](#bib11){ref-type="other"}). The results show that there was no association between plant lignan intake and overall risk, and this association was subjected to marked heterogeneity. However in post-menopausal women, there is a small but significant reduction in risk and a reduction in heterogeneity. A significantly decreased risk with increasing enterolignan exposure was also found. However, there was significant heterogeneity between studies making it difficult to draw clear conclusions, and the effect did not persist when analyses were stratified by menopausal status, although the number of studies included in these stratified analyses was very small. Finally, there was no association between enterolactone concentrations in blood and overall risk, or when analysis was stratified by menopausal status.

The protective action of plant lignans against breast cancer in post-menopausal, but not in pre-menopausal women, would suggest that lignan activity has a physiologic effect only at low oestradiol levels. One of the mechanisms of action may be greater sex hormone-binding globulin production and binding of free oestradiol ([Adlercreutz *et al*, 1989](#bib3){ref-type="other"}, [1992](#bib4){ref-type="other"}; [Zeleniuch-Jacquotte *et al*, 2004](#bib63){ref-type="other"}; [Low *et al*, 2007](#bib35){ref-type="other"}). Binding of type II nuclear oestrogen receptor ([Adlercreutz *et al*, 1992](#bib4){ref-type="other"}; [Adlercreutz, 2007](#bib1){ref-type="other"}) and altering oestrogen synthesis within the breast cells and extragonadal sites, such as the adipose tissue, are other possible mechanisms ([Adlercreutz *et al*, 1993](#bib2){ref-type="other"}; [Saarinen *et al*, 2007](#bib49){ref-type="other"}). Enterolactone has been shown to decrease local oestrogen production by inhibiting 17-hydroxysteroid dehydrogenase type I and aromatase ([Wang *et al*, 1994](#bib60){ref-type="other"}; [Brooks and Thompson, 2005](#bib9){ref-type="other"}).

The apparent protective effect of dietary plant lignans in post-menopausal women is not supported by the findings from the meta-analysis of studies that measured the enterolactone levels in their blood. It would be expected that women consuming larger amounts of plant lignans would have a higher circulating concentration of enterolactone. There are a number of possible reasons for this disparity. Dietary intake of plant lignans was assessed on the basis of the subjects\' self-reported dietary intake ranging from 6 months before study entry ([Hedelin *et al*, 2008](#bib20){ref-type="other"}) to 3 years before breast cancer diagnosis, ([dos Santos Silva *et al*, 2004](#bib14){ref-type="other"}) and thus, it reflects long-term intake. Enterolactone concentration that is measured in a single blood sample may be more indicative of recent dietary habits. There may also be a significant intra-individual variation in serum response to dietary intake of plant lignans ([Hausner *et al*, 2004](#bib19){ref-type="other"}). For example, blood levels of enterolactone can be modulated by age, smoking, frequency of defecation, weight--obesity--body mass index and regular alcohol intake ([Kilkkinen *et al*, 2001](#bib30){ref-type="other"}, [2002](#bib29){ref-type="other"}; [Horner *et al*, 2002](#bib22){ref-type="other"}; [Milder *et al*, 2007](#bib41){ref-type="other"}), and these factors could potentially differ by menopausal status (in particular, age and body mass index). As bacterial enzymes are involved in lignan metabolism, the use of antibiotics has also been shown to affect enterolactone serum concentration ([Kilkkinen *et al*, 2002](#bib29){ref-type="other"}); antibiotic use was generally not controlled for in these studies.

It is also possible that the protective effect is caused directly by the plant lignans or chemicals within the metabolic pathway other than enterolactone, or even by a synergistic effect between plant lignans and enterolignans. However, other food constituents found to be associated with plant lignans may exert the effect. For example, *α*-linoleic acid, which is also thought to have anti-cancer effects ([Thompson, 2003](#bib53){ref-type="other"}; [Bougnoux and Chajes, 2003](#bib8){ref-type="other"}, p. 232), is found in very high levels in flaxseed, the richest source of plant lignans ([Thompson *et al*, 1991](#bib55){ref-type="other"}).

Determining plant lignan intake has various limitations, which could lead to an over- or under-estimation of food content. Some food composition databases are incomplete in terms of not containing values for the more recently discovered plant lignans (e.g., medioresinol) or for the whole range of foods consumed by the study population. In addition, there are various analytical methods for determining food values ; hence, databases compiled from published values determined by different methodologies may contain inherent errors. It has also been shown that the amount of lignans in food can differ according to crop variety, location, year of harvest and processing ([Thompson *et al*, 1997](#bib54){ref-type="other"}; [Kuijsten *et al*, 2005](#bib32){ref-type="other"}). Dietary measurement error associated with FFQs (food frequency questionnaires) is also possible. FFQs that were used varied in length, ranging from 67 to 208 items. Only one study validated its FFQ specifically for plant lignan assessment ([Torres-Sanchez *et al*, 2008](#bib56){ref-type="other"}), although a UK study used the combination of an FFQ and 24-h recalls to group participants into quartiles of intake ([dos Santos Silva *et al*, 2004](#bib14){ref-type="other"}). In addition, the possibility of residual confounding cannot be ruled out.

Consumption of soy food, rich in isoflavones, has been shown to reduce breast cancer risk in Asian women but not in Western women ([Wu *et al*, 2008](#bib62){ref-type="other"}), suggesting that ethnicity may play a role in this effect. It is not known whether there are differential physiologic effects of lignans in people of different races, although there is some evidence of variation in the urinary excretion of lignans between white, African American and Latino women ([Horn-Ross *et al*, 1997](#bib23){ref-type="other"}). Of the 23 articles used for the meta-analyses, only 3 American studies provided complete data with regard to ethnicity ([Horn-Ross *et al*, 2001](#bib25){ref-type="other"}, [2002](#bib24){ref-type="other"}; [McCann *et al*, 2004](#bib40){ref-type="other"}); hence, it was impossible perform sub-analyses for examining this.

In summary, the meta-analyses presented in this study, indicate that plant lignans and enterolignans are unlikely to significantly protect all women against breast cancer development. However, our results suggest that high plant lignan intake is associated with a 15% decreased risk in post-menopausal women, which is a small reduction that could be due to residual confounding. If real, the reason for the selective effect is not clear. Additional studies of the effect of lignan exposure on post-menopausal breast cancer risk are needed to confirm these findings before reassessing the current dietary guidelines.

Part of this work was supported by funding from the Against Breast Cancer charity (Registered Charity No. 1121258).
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###### 

Characteristics of studies included in the review of plant lignans and breast cancer risk

  **First author/ (year)/ country**                                            **Parent study**                         **Study design (follow-up)**                                 **Cases**   **Controls/ cohort size**   **Menopausal status**   **Lignans measured**   **Dietary assessment**                                 **Adjusted confounders**
  ---------------------------------------------------------------------------- ---------------------------------------- ------------------------------------------------------------ ----------- --------------------------- ----------------------- ---------------------- ------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------
  [Horn-Ross *et al* (2002)](#bib24){ref-type="other"} United States           California Teachers Study                Prospective cohort (222 249 person-years; 2 years^\*\*^)     711         111 526                     Pre-M and Post-M        M, S                   Self-reported 113-item FFQ                             Age at 1st birth and menarche, BMI, daily caloric intake, ethnicity, family history, menopausal status, nulliparity, physical activity
  [Touillaud *et al* (2006)](#bib58){ref-type="other"} France                  E3N Study                                Prospective cohort (117 652 person-years; 4.2 years^\*^)     402         26 868                      Pre-M                   M, S, P, L             Self-reported 208-item FFQ                             Age at 1st birth and at menarche, alcohol, BBD, BMI, education, family history, energy, geographic area, height, OC, parity
  [Touillaud *et al* (2007)](#bib57){ref-type="other"} France                  E3N Study                                Prospective cohort (383 425 person-years; 7.7 years^\*^)     1469        58 049                      Post-M                  M, S, P, L             Self-reported 208-item FFQ                             Age at 1st birth, at menarche menopause, alcohol, BBD, BMI, energy, family history, height, HRT, OC, parity, smoking
  [Hedelin *et al* (2008)](#bib20){ref-type="other"} Sweden                    SWLH cohort                              Prospective cohort (13 years)                                1014        1014                        Pre-M and Post-M        M, S, P, L, Sy, Med    Self-reported 80-item FFQ                              Age at menarche and 1st pregnancy, alcohol, BMI, energy, family history, OC, parity, saturated fat
  [Suzuki *et al* (2008)](#bib51){ref-type="other"} Sweden                     SMC Study                                Prospective cohort (430 339 person-years; 8.3 years^\*\*^)   1284        51 823                      Post-M                  M, S, P, L             Self-reported 67-item FFQ (1987), 93-item FFQ (1997)   Age at 1st birth, menarche and menopause, alcohol, BBD, BMI, education, energy, family history, height, HRT, OC, parity
  [Horn-Ross *et al* (2001)](#bib25){ref-type="other"} United States           Bay Area Breast Cancer Study             Population-based case--control                               1272        1610                        Pre-M and Post-M        M, S                   Self-reported 94-item FFQ                              Age, age at menarche, BBD, BMI, daily caloric intake, education, family history, HRT, lactation, menopausal status, parity, race
  [dos Santos Silva *et al* (2004)](#bib14){ref-type="other"} United Kingdom                                            Case--control (GP\'s patient lists)                          240         477                         Pre-M and Post-M        M, S                   Interviewed 207-item FFQ                               Age at 1st birth and at menarche, education, family history, lactation, menopausal status, parity
  [Linseisen *et al* (2004)](#bib34){ref-type="other"} Germany                                                          Population-based case--control                               278         666                         Pre-M                   M, S                   Self-reported 176-item FFQ                             Alcohol, BMI, education, energy, family history, lactation, parity
  [McCann *et al* (2004)](#bib40){ref-type="other"} United States              WEB Study                                Population-based case--control                               1122        2036                        Pre-M and Post-M        M, S                   Self-reported 98-item FFQ                              Age, age 1st birth, at menarche and menopause, BBD, BMI, education, energy, age at menopause, parity, race, smoking
  [Fink *et al* (2007)](#bib16){ref-type="other"} United States                LIBCSP Study                             Population-based case--control                               1434        1404                        Pre-M and Post-M        M, S                   Self-reported 94-item FFQ                              Age and energy
  [Cotterchio *et al* (2008)](#bib10){ref-type="other"} Canada                 Ontario Women\'s Diet and Health Study   Population-based case--control                               3063        3370                        Pre-M and Post-M        M, S, P, L             Self-reported 178-item FFQ                             Age, age at 1st live birth, BBD, dietary fibre intake, family history, HRT
  [Torres-Sanchez *et al* (2008)](#bib56){ref-type="other"} Mexico                                                      Hospital based case--control                                 141         141                         Pre-M and Post-M        M, S, P, L             Interviewed 100-item FFQ                               Age, energy, lifetime lactation, menopause status

BBD=benign breast disease; BMI=body mass index; E3N=French Component of the European Prospective Investigation into Diet and Cancer (EPIC) Study; FFQ=food frequency questionnaire; GP=general practitioner; HRT=hormone replacement therapy; L=lariciresinol; LIBCSP=Long Island Breast Cancer Study Project; M=matairesinol; Med=medioresinol; OC=oral contraceptive; P=pinoresinol; Peri-M=peri-menopausal; Pre-M=pre-menopausal; Post-M=post-menopausal; S=secoisolariciresinol; SMC=Swedish Mammography Cohort; SWLH=Scandinavian Women\'s Lifestyle and Health Cohort; Sy=syringaresinol; WEB=Western New York Exposure and Breast Cancer Study.

^\*^Median follow-up; ^\*\*^Mean follow-up.

###### 

Characteristics of studies included in the review of mammalian enterolignans (enterolactone and enterodiol) and breast cancer risk

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **First author/ (year)/ country**                                         **Parent study**   **Study design (median follow-up)**   **Cases**   **Controls/ cohort size**   **Menopausal status**               **Diet assessment**          **Adjusted confounders**
  ------------------------------------------------------------------------- ------------------ ------------------------------------- ----------- --------------------------- ----------------------------------- ---------------------------- -------------------------------------------------------------------------------------------------------------------------------------------
  [Keinan-Boker *et al* (2004)](#bib28){ref-type="other"} The Netherlands   Prospect- EPIC     Prospective Cohort (5.2 years)        280         80 215                      Pre-M, Peri-M and Post-M combined   Self-reported 178-item FFQ   Age at 1st birth and study entry, education, energy, height, HRT, marital status, OC, parity, physical activity, weight

  [Touillaud *et al* (2006)](#bib58){ref-type="other"} France               E3N Study          Prospective Cohort (4.2 years)        402         117 652                     Pre-M                               Self-reported 208-item FFQ   Age at 1st birth and menarche, alcohol, BBD, BMI, education, energy, family history, geographic area, height, OC, parity

  [Touillaud *et al* (2007)](#bib57){ref-type="other"} France               E3N Study          Prospective cohort (7.7 years)        1469        383 425                     Post-M                              Self-reported 208-item FFQ   Age at 1st birth, at menarche and menopause, alcohol, BBD, BMI, energy, family history, geographic area, height, HRT, OC, parity, smoking

  [McCann *et al* (2002)](#bib39){ref-type="other"} United States           WEB Study          Population-based case--control        301 439     316 494                     Pre-M\                              FFQ                          Age at menarche, BBD, BMI, education, energy, family history, parity; further adjusted for age at menopause
                                                                                                                                                                             Post-M                                                           

  [Linseisen *et al* (2004)](#bib34){ref-type="other"} Germany                                 Population-based case--control        278         666                         Pre-M                               Self-reported 176-item FFQ   Alcohol, BMI, breast-feeding, education, energy, family history, parity; controls matched by exact age to cases
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

BBD=benign breast disease; BMI=body mass index; E3N=French Component of the European Prospective Investigation into Diet and Cancer (EPIC) Study; FFQ=food frequency questionnaire; HRT=hormone replacement therapy; OC=oral contraceptive use; Peri-M=Peri-menopausal; Pre-M=pre-menopausal; Post-M=post-menopausal; Prospect-EPIC=Dutch Cohort of EPIC Study; WEB=Western New York Exposure and Breast Cancer Study.

###### 

Characteristics of studies included in the review of enterolactone exposure as measured in blood and breast cancer risk

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **First author/ (year)/ country**                                              **Parent study**                     **Design (follow-up)**                                  **Cases**   **Controls/ cohort size**   **Method**   **Menopausal status**   **Mean ENL cases (nmol/l)**    **Mean ENL controls/cohort (nmol/l)**   **Adjusted confounders**
  ------------------------------------------------------------------------------ ------------------------------------ ------------------------------------------------------- ----------- --------------------------- ------------ ----------------------- ------------------------------ --------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------
  [Boccardo *et al* (2003)](#bib7){ref-type="other"} Italy                                                            Prospective cohort (6.5 years after cyst aspiration)    18          383                         TR-FIA       Pre-M and Post-M        14.7                           19.6                                    Age, cyst type and family history

  [Hultén *et al* (2002)](#bib26){ref-type="other"} Sweden                       VIP, MONIKA and MSP studies          Nested case--referent                                   248         492                         TR-FIA       Pre-M and Post-M        26.8 VIP and MONIKA 19.3 MSP   22.9 VIP and MONIKA 20.4 MSP            BMI, menopausal status, smoking

  [Kilkkinen *et al* (2004)](#bib31){ref-type="other"} Finland                   Cross-sectional population surveys   Nested case--control                                    206         215                         TR-FIA       Pre-M and Post-M        25.2                           24.0                                    None

  [Olsen *et al* (2004)](#bib44){ref-type="other"} Denmark                       Diet, Cancer and Health Study        Nested case--control                                    381         381                         TR-FIA       Post-M                  Not provided                   Not provided                            Age, HRT (through matching of controls)

  [Zeleniuch-Jacquotte *et al* (2004)](#bib63){ref-type="other"} United States   NYU Women\'s Health Study            Nested case--control                                    417         417                         TR-FIA       Pre-M\                  18.3\                          15.1\                                   Age at 1st live birth and menarche, ln(BMI), family history, ln(height), nulliparity
                                                                                                                                                                                                                                   Post-M                  18.6                           18.9                                    

  [Verheus *et al* (2007)](#bib59){ref-type="other"} The Netherlands             Prospect-EPIC                        Nested case--control                                    383         383                         LC/MS        Pre-M/Peri-M\           2.98 (ng/ml)\                  2.66(ng/ml)\                            Age at menarche and family history (Pre-M) Crude OR (Post-M).
                                                                                                                                                                                                                                   Post-M                  2.71 (ng/ml)                   2.65 (ng/ml)                            

  [Ward *et al* (2008)](#bib61){ref-type="other"} United Kingdom                 EPIC-Norfolk                         Nested case--control (9.5 years; 11 261 person-years)   219         891                         LC/MS        All                     5.83 (ng/ml)^\*^               5.00 (ng/ml)^\*^                        Age, age at menarche, breast-feeding, energy, family history, fat, HRT, OC, menopausal status, parity, social class, weight

  [Pietinen *et al* (2001)](#bib45){ref-type="other"} Finland                    Kuopio Breast Cancer Study           Population-based case--control                          194         208                         TR-FIA       Pre-M\                  16.6\                          20.7\                                   Age at 1st birth and at menarche, alcohol, area, BBD, BMI, education, family history, HRT, OC, physical activity, smoking, waist to hip ratio
                                                                                                                                                                                                                                   Post-M                  21.2                           28.9                                    

  [Piller *et al* (2006a)](#bib46){ref-type="other"} Germany                                                          Population-based case--control                          192         231                         TR-FIA       Pre-M                   11.6                           12.2                                    Age at menarche, alcohol, BMI, breast-feeding, day of analysis, education, family history, OC, parity, time difference between surgery and blood sampling day
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

BBD=benign breast disease; BMI=body mass index; ENL=enterolactone; HRT=hormony replacement therapy; LC=liquid chromatography; MONIKA=Monitoring of Trends and Cardiovascular Disease Study; MS=mass spectrometry; MSP=Mammary Screening Project; NYU=New York University; OC=oral contraceptive; Peri-M=peri-menopausal; Pre-M=pre-menopausal; Post-M=post-menopausal; Prospect-EPIC=Dutch Cohort of the European Prospective Investigation into Diet and Cancer (EPIC) Study; TR-FIA=time-resolved fluoroimmunoassay; VIP=Västerbotten Intervention Project.

^\*^Median values. Mean values not provided.
